What is Monopar Therapeutics's commitments & contingencies?

Monopar Therapeutics (MNPR) reported commitments & contingencies of $0 in Q3 2021.

Monopar Therapeutics MNPR Commitments & Contingencies

Commitments & Contingencies at other companies

Tandem Diabetes CareTNDM

$0—

HagertyHGTY

$0—

Global Net LeaseGNL

$0—

W&T OffshoreWTI

$25.75M+27.5%

FIP

FTAI Infrastructure Inc.FIP

$0—

OGS

ONE GASOGS

$0—

Other financials

Income statement

See full

Revenue-—

Operating income-$5.2M-62.2%

Net income-$3.9M-48.3%

EPS (diluted)-$0.19—

Balance sheet

See full

Cash & equivalents$52.5M+32.3%

Total debt$230.4K+2,692%

Total equity$135.4M+153%

Total assets$138.0M+150%

Cash flow

See full

Operating cash flow-$3.5M+38.7%

Valuation

See full

Market cap$587.04M+192%

Enterprise value$534.72M+232%

Returns & leverage

See full

Return on equity-15.9%-6.6pp

Debt / equity0×0.0×

Current ratio56×—

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommitmentsAndContingencies.

The official record: Monopar Therapeutics’s 10-Q, filed November 12, 2021, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's commitments & contingencies.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monopar Therapeutics's commitments & contingencies?: Monopar Therapeutics (MNPR) reported commitments & contingencies of $0 in Q3 2021.